Apollo Hospitals Enterprises sales up 12% Y-o-Y

A robust contribution to growth was from new hospitals especially Navi Mumbai, Malleswaram, Trichy, Vizag, Nashik and Nellore

Apollo hospitals have recently released Q3 highlights. Third quarter PAT rose 2 per cent and Q3 Sales gained 12 per cent Y-o-Y on a consolidated basis. Reportedly, overall occupancy across the group was 67 per cent. The occupancy in mature hospitals was 70 per cent while new hospitals had occupancy at 60 per cent. The group informed a robust contribution to growth from new hospitals especially Navi Mumbai, Malleswaram, Trichy, Vizag, Nashik and Nellore.

Commenting on the results, Suneeta Reddy, MD, AHEL said, “We are heartened by the performance of our new units like Navi Mumbai, Malleshwaram and Vizag, and we look forward to continued traction from them. We expect that the effects of demonetisation, regulatory price caps and GST, while largely managed, will be fully recouped by the end of FY19. We continue to focus on clinical differentiation and quality of care as our mainstays and are confident of the payoff from this in our existing large hospitals like Chennai, Hyderabad, Bangalore, Delhi and Kolkatta over the course of next year.  Our strategy of focusing on high end tertiary care cases has resulted in higher growth in Cardiac procedures, Transplants, Neurosciences, Orthopedic Implants and Paediatric this year – which we would continue to build upon over the next year as well.We have definitive plans to shore up our Oncology volumes and revenues over the next 3-5 years to become a national leader in this space both in terms of clinical outcomes and volumes.”

In the consolidated Q3FY18 performance, PAT grew by 2 per cent to Rs 438 million compared to Rs 429 million in Q3FY17, Revenues were higher by 12 per cent to Rs 21,393 million compared to Rs 19,057 million in Q3FY17, EBITDA grew 17 per cent to Rs. 2,172 million against Rs 1,860 million in Q3FY17, EBITDAR grew by 17 per cent to Rs 2,934 million as against Rs 2,509 million in Q3FY17 and Diluted EPS of Rs. 3.15 per share in Q3FY18

The company posted its standalone Q3FY18 performance stating PAT at Rs 674 million compared to Rs. 728 million in Q3FY17. Revenues grew by 13 per cent to Rs 18,961 million compared to Rs 16,806 million in Q3FY17, EBITDA grew by 14 per cent to Rs 2,213 million as against Rs 1,941 million in Q3FY17, EBITDAR was higher by 14% to Rs. 2,760 million as against Rs. 2,414 million in Q3FY17 and Diluted EPS of Rs. 4.85 per share in Q3FY18.